Trial · NCT07893535
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
NCT07893535, Phase 1, Not yet recruiting, BeOne Medicines
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors. Trials, record NCT07893535. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893535
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
- NCT number
- NCT07893535
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 96 participants, estimated
- Lead sponsor
- BeOne Medicines
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- BON-106
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Escalation Phase: Number of Participants with Dose-limiting Toxicities (DLTs) | Up to approximately 1 month | |
| Primary | Dose Escalation Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs) | From first dose of study drug until 30 days after last dose, up to approximately 24 months. | |
| Primary | Dose Expansion Phase: Objective Response Rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) with confirmation per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. |
| Secondary | Dose Escalation Phase: Objective Response Rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) with confirmation per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. |
| Secondary | Duration of Response (DOR) | Up to approximately 24 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) at Week 12 and Week 24 | Week 12 and Week 24 | DCR at 12 weeks and 24 weeks is defined as the percentage of participants who have CR, PR, or stable disease (SD) according to RECIST v1.1, and are alive and progression-free at the Week 12 and Week 24 assessment, respectively. |
| Secondary | Dose-Expansion Phase: Progression-free Survival (PFS) | Up to approximately 24 months | PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Serum Concentration of BON-106 | Up to approximately 24 months | |
| Secondary | Maximum Observed Concentration of BON-106 | Approximately 2 months | |
| Secondary | Area Under the Concentration-time Curve (AUC) of BON-106 | Approximately 2 months |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893535
GET https://conductscience.org/api/trials/v1/NCT07893535/registered